• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Alfred Romann

Articles by Alfred Romann

Biosimilars unlikely to impact poorer markets

Dec. 23, 2015
By Cornelia Zou and Alfred Romann
HONG KONG – Fear of biosimilars, drugs that once launched will potentially capture entire markets with their discounted prices, is not likely to be an issue in some of the poorer countries in Asia and Latin America, where even cheaper biosimilars are too expensive for the general public. With numerous patient access challenges, biosimilars have had a difficult time finding their footing in some of these markets.
Read More

Biosimilars unlikely to impact poorer markets

Dec. 22, 2015
By Cornelia Zou and Alfred Romann
HONG KONG – Fear of biosimilars, drugs that once launched will potentially capture entire markets with their discounted prices, is not likely to be an issue in some of the poorer countries in Asia and Latin America, where even cheaper biosimilars are too expensive for the general public. With numerous patient access challenges, biosimilars have had a difficult time finding their footing in some of these markets.
Read More

China's Luye up 10% on U.S. FDA clearance of schizophrenia NDA

Oct. 14, 2015
By Alfred Romann
HONG KONG – Chinese biopharmaceutical company Luye Pharma Group Ltd. (LPG) spiked in Hong Kong trading last week after getting a green light from the U.S. FDA on the new drug application (NDA) for an investigational schizophrenia drug.
Read More

South Korea's Alteogen inks deal with 3Sbio for ADC targeting HER2

Oct. 14, 2015
By Alfred Romann and Haky Moon
HONG KONG – In a deal that is likely to open the door of the Chinese and global market to an early stage South Korean drug developer, 3Sbio Inc (HK:2530) signed an exclusive agreement to develop, manufacture and market an antibody-drug conjugate (ADC) that targets the HER2 pathway for cancer. The deal with Alteogen Inc. (KS:196170), of Daejeon, South Korea, covers Mainland China, Hong Kong and Macau and includes an undisclosed up-front payment as well as further milestone payments and royalties for the development of ALT-P7.
Read More

South Korea's Alteogen inks deal with 3Sbio for ADC targeting HER2

Oct. 13, 2015
By Alfred Romann and Haky Moon
HONG KONG – In a deal that is likely to open the door of the Chinese and global market to an early stage South Korean drug developer, 3Sbio Inc (HK:2530) signed an exclusive agreement to develop, manufacture and market an antibody drug conjugate (ADC) that targets the HER2 pathway for cancer.
Read More

China's Luye up 10% on U.S. FDA clearance of schizophrenia NDA

Oct. 12, 2015
By Alfred Romann
HONG KONG – Chinese biopharmaceutical company Luye Pharma Group Ltd. (LPG) spiked in Hong Kong trading last week after getting a green light from the U.S. FDA on the new drug application (NDA) for an investigational schizophrenia drug.
Read More

India/China Talent War: Brain drain or research exchange? China, India sharing and competing

Sep. 18, 2015
By Alfred Romann

Looking to repeat Pharma successes in Med-Tech: China is rapidly transforming itself into major player in medical technology space

Sep. 16, 2015
By Alfred Romann and Cornelia Zou

Asia In the Spotlight: Deep discount pricing in China in danger with anti-corruption scrutiny

July 21, 2015
By Alfred Romann

Asia in the Spotlight: CFDA's Tong Min becomes latest official under investigation

June 4, 2015
By Alfred Romann
Previous 1 2 3 4 5 6 7 8 9 10 11 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 9, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • NME Digest: Q1 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe